Skip to main content
SpringerLink
Log in

Applications of Haploidentical SCT in Patients with Non-malignant Diseases

  • Chapter
  • First Online:
Haploidentical Stem Cell Transplantation

Part of the book series: Stem Cell Biology and Regenerative Medicine ((STEMCELL))

  • 365 Accesses

Abstract

Novel methods of T-cell depletion either ex – or in-vivo has led to an increase use of haploidentical donor for allogeneic stem cell transplantation in patients with non-malignant diseases, who are lacking a HLA identical sibling or compatible unrelated donor. T-cell depletion by CD34+ cell selection resulted in relative high risk of graft failure with exception of SCIDs. Further refinement has been reported for selected depletion of α/β T-cells and CD19/B-lymphocytes. Risk of graft failure is relative high, but may be overcome by suicide gene-modified T-cells after haploidentical stem cell transplantion. T-cell repleted stem cell transplantation is an alternative method either with Anti-Thymocyte Globulin or post-transplant cyclophosphamide for haploidentical stem cell transplantation. Here the incidence of GvHD seems to be higher and longer follow-up is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017. doi: 10.1038/bmt.2017.34. [Epub ahead of print].

  2. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(14):339–49.

    Article  CAS  PubMed  Google Scholar 

  3. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186–93.

    Article  CAS  PubMed  Google Scholar 

  4. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38(4):291–7.

    Article  PubMed  Google Scholar 

  5. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456–64.

    Article  CAS  PubMed  Google Scholar 

  6. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-hapolidentical stem cell transplantation after removal of α/β+ T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–6.

    Article  CAS  PubMed  Google Scholar 

  7. Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLorman D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20(11):1711–6.

    Article  PubMed  Google Scholar 

  8. Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50(5):685–9.

    Article  CAS  PubMed  Google Scholar 

  9. Xu LP, Wang SQ, Wu DP, Wang JM, Gao SJ, Jiang M, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicenter prospective study. Br J Haematol. 2016;175(2):265–74.

    Article  PubMed  Google Scholar 

  10. Gao L, Li Y, Zhang Y, Chen X, Gao L, Zhang C, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without invitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transplant. 2014;49(4):519–24.

    Article  CAS  PubMed  Google Scholar 

  11. Xu LP, Jin S, Wang SQ, Xia LH, Bai H, Gao SJ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Sodanin P, Isgro A, Gaziev J, Polchi P, Paciaroni K, Marziali M, et al. Purified T-depleted CD34+ peripheral blood and bone marrow celltransplantation from haploidentical mother to child with thalassemia. Blood. 2010;115(6):1296–302.

    Article  Google Scholar 

  13. Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, et al. Hematopoietic stem cell transplantation for homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016;51(6):813–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013;19(5):820–30.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic disease. Bone Marrow Transplant. 2008;42(8):523–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61(2):341–8.

    CAS  PubMed  Google Scholar 

  18. Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone transplants without pretransplant chemotherapy or post-transplant GvHD prophylaxis. J Pediatr. 2009;155(6):834–40.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haematopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361(9357):553–60.

    Article  PubMed  Google Scholar 

  20. Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, et al. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood. 2012;119(12):2949–55.

    Article  CAS  PubMed  Google Scholar 

  21. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severee combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371(5):434–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Merli P, Bartaina A, Li Pira G, Pende D, Falco M, Pagliana D, et al. Infusion of donor cells transduced with inducible Caspase 9 (BPX-501 cells) is a safe and effective strategy to accelerate immune recovery in patients with non-malignant disorders after T cell depleted haplo-HSCT. Bone Marrow Transplant. 2016;51:S4–5.

    Google Scholar 

  23. Jaiswal SR, Chakrabarti A, Chatterjee S, Ray K, Chakrabarti S. Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: the need to look beyondpost-transplantation cyclophosphamide in younger children. Pediatr Transplant. 2016;20(5):675–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246, Hamburg, Germany

    Nicolaus Kröger

Authors
  1. Nicolaus Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolaus Kröger .

Editor information

Editors and Affiliations

  1. Department of Hematology, Ankara University Medical School, Sıhhiye, Ankara, Turkey

    Taner Demirer

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Kröger, N. (2017). Applications of Haploidentical SCT in Patients with Non-malignant Diseases. In: Demirer, T. (eds) Haploidentical Stem Cell Transplantation. Stem Cell Biology and Regenerative Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-65319-8_10

Download citation

Publish with us

Policies and ethics

Search

Navigation